CIA
ADMA icon

Concurrent Investment Advisors’s ADMA Biologics ADMA Stock Holding History

Concurrent Investment Advisors’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-11,095
Closed -$202K – 1498
2025
Q2 		$202K Buy
11,095
+973
+10% +$19.8K ﹤0.01% 1261
2025
Q1 		$201K Buy
+10,122
New +$175K ﹤0.01% 1128

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
SHCM
Sachem Head Capital Management New York $4.82B AUM 73.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Concurrent Investment Advisors's ADMA Position: Q3 2025 in Review

Concurrent Investment Advisors sold out of ADMA Biologics (ADMA) in Q3 2025, closing a stake of 11,095 shares — an estimated $202K sold.

Concurrent Investment Advisors first reported a position in ADMA in Q1 2025 and held it in 2 quarters. The position peaked at $202K in Q2 2025. 365 funds tracked by Wall St. Rank hold ADMA as of Q3 2025.

  • Concurrent Investment Advisors reported no remaining ADMA Biologics position as of Q3 2025 after selling out during the quarter.
  • Concurrent Investment Advisors sold 11,095 ADMA Biologics shares in Q3 2025, an estimated $202K.
  • Concurrent Investment Advisors first reported a position in ADMA Biologics in Q1 2025 and held it in 2 quarters.
  • Concurrent Investment Advisors's ADMA Biologics position peaked at $202K in Q2 2025.
  • 365 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2025.

Based on Concurrent Investment Advisors's 13F filing for Q3 2025, filed 27 Oct 2025.